home / stock / sabs / sabs news

SABS News and Press, SAB Biotherapeutics Inc. From 01/19/23

Stock Information
Company Name: SAB Biotherapeutics Inc.
Stock Symbol: SABS
Market: NASDAQ
Website: sabbiotherapeutics.com
Menu
SABS SABS Quote SABS Short SABS News SABS Articles SABS Message Board
Get SABS Alerts

News, Short Squeeze, Breakout and More Instantly...
SABS - SAB Biotherapeutics CEO Eddie Sullivan, PhD, to Present Next Generation Biologics in Immunology at BIO CEO & Investor Conference

SIOUX FALLS, S.D., Jan. 19, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS ), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, high-avidity, fully-human polyclonal antibodies without the need for ...
SABS - SAB Biotherapeutics gets additional $8.2M in funding in closeout DoD contract

SAB Biotherapeutics ( NASDAQ: SABS ) has received an additional $8.2M from the U.S. Department of Defense related to the closeout of the discontinued COVID-19 prototype research and development contract. This brings the total final closeout settlement to $16.8M received since Nove...

SABS - SAB Biotherapeutics Receives an Additional $8.2 Million in Closeout of DoD Contract

SIOUX FALLS, S.D., Jan. 18, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics ( Nasdaq: SABS ), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, high-avidity, fully-human polyclonal antibodies without the need for hum...

SABS - SAB Biotherapeutics Successfully Concludes IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes

SIOUX FALLS, S.D., Jan. 10, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), ("SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, high-avidity, fully-human polyclonal antibodies (hpAB) wit...
SABS - SAB Biotherapeutics' CMO Alexandra Kropotova to Deliver Presentation on Next Generation Biologics in Immunology at Biotech Showcase

SIOUX FALLS, S.D., Jan. 09, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS ), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, high-avidity, fully-human polyclonal antibodies without the need for ...

SABS - SAB Biotherapeutics Novel DiversitAb(TM) Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases

SIOUX FALLS, S.D., Jan. 05, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS ), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors,&...

SABS - SAB Biotherapeutics CMO Selected to Present at the January 2023 Biotech Showcase in San Francisco

SIOUX FALLS, S.D., Dec. 15, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS ), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, high-avidity, fully-human polyclonal antibodies without the need for ...
SABS - SAB Biotherapeutics announces $7.9M private placement of stock

SAB Biotherapeutics ( NASDAQ: SABS ) on Wednesday announced a private placement of ~7.3M shares and warrants to buy an equal number of shares for aggregate gross proceeds of ~$7.9M. Existing SAB ( SABS ) investors and new institutional investors participated in the privat...

SABS - SAB Biotherapeutics Announces $7.9 Million Private Placement of Common Stock

SIOUX FALLS, S.D., Dec. 07, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, toda...

SABS - SAB Biotherapeutics Initiates IND-Enabling GLP Toxicology Study for SAB-142, Novel Immunotherapeutic for Type 1 Diabetes

SIOUX FALLS, S.D., Nov. 21, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), ("SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need f...
Previous 10 Next 10